• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Advances in urology >The Role of Chemotherapy in Upper Tract Urothelial Carcinoma
【24h】

The Role of Chemotherapy in Upper Tract Urothelial Carcinoma

机译：化疗在上部尿路上皮癌中的作用

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Locally advanced upper tract urothelial carcinoma has a poor prognosis. While surgery represents the only potentially curable therapeutic intervention, recurrences are common and typically systemic in nature. It is thus reasonable to consider perioperative chemotherapy in an effort to decrease the risk of recurrence. There are very little direct data providing clinical guidance in this scenario. For urothelial cancer of the bladder, there are randomized phase III data demonstrating a survival advantage with neoadjuvant cisplatin-based combination chemotherapy. Although arguments favoring adjuvant chemotherapy could be made for upper tract urothelial cancer, the loss of renal function that occurs with nephrectomy can complicate administration of appropriate perioperative treatment. Therefore, by analogy to urothelial carcinoma of the lower tract, it is argued that cisplatin-based neoadjuvant chemotherapy should be the standard of care for patients with locally advanced upper tract urothelial cancer.
机译：局部晚期的上部尿路上皮癌预后差。虽然手术代表唯一潜在的治疗治疗干预，但复发性是常见的，通常是全身的。因此，考虑围手术期化疗，以减少复发风险。在这种情况下，在这种情况下提供了临床指导的直接数据。对于膀胱的尿路上癌，随机阶段III数据，证明了基于Neoadjuvant顺铂的组合化疗的存活优势。虽然可以对上部道尿路上皮癌进行辅助化疗的争论，但肾切除术发生的肾功能丧失可以使适当的围手术期治疗的给药复杂化。因此，通过比较低下节的尿路上皮癌，认为基于顺铂的新辅助化疗应该是局部晚期患者的护理标准。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号